In the earlier days of the pandemic, the race was on. Companies rushed to bring a coronavirus vaccine through development and to market, and investors rushed to invest in these potential vaccine makers. As a result, back in 2020, biotech hopefuls including (NASDAQ: MRNA), Novavax, and BioNTech (NASDAQ: BNTX) -- and even some smaller players -- saw their shares soar.

In recent times, though, investors have shied away from vaccine makers and potential vaccine makers. Demand for shots has declined, and that's prompted them to worry about these companies' revenues -- or potential revenues -- in a post-pandemic setting.

Still, the coronavirus hasn't disappeared. At the same time, the vaccine market is undergoing a dramatic change. In this new context, do vaccine stocks still make good investments? Let's find out.

Continue reading

Source Fool.com